A novel study design for antibiotic trials in acute exacerbations of copd:Maestral methodology

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 373-383

  Wilson, Robert ^a   Anzueto, Antonio ^b   Miravitlles, Marc ^c   Arvis, Pierre ^d   Faragó, Geneviève ^e   Haverstock, Daniel ^f   Trajanovic, Mila ^e   Sethi, Sanjay ^g  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d Bayer Health Care ^*  (France)

^e Bayer Inc   (Canada)

^f BAYER CORPORATION   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

Author keywords

AECOPD; Amoxicillin clavulanic acid; Antibiotic; Clinical trial design; Exacerbation; Moxifloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; MOXIFLOXACIN; PREDNISOLONE; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ACUTE DISEASE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT CARE; PATIENT ASSESSMENT; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AMBULATORY CARE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; EUROPE; HOSPITALIZATION; LUNG; METHODOLOGY; MICROBIOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADRENAL CORTEX HORMONES; AMBULATORY CARE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BRONCHODILATOR AGENTS; CANADA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; LUNG; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLINES; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 81055123895     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S21071     Document Type: Article

References (44)

1. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
2. Kanner RE, Anthonisen NR, Connett JE; For the Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164(3):358-364.
3. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther. 2006;4(1):101-124.
4. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931.
5. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4(7):554-564.
6. Ramsey SD, Hobbs FD. Chronic obstructive pulmonary disease, risk factors, and outcome trials:comparisons with cardiovascular disease. Proc Am Thorac Soc. 2006;(7)3:635-640.
7. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med. 2006;119(10 SUPPL. 1):S38-S45.
8. Llor C, Molina J, Naberan K, Cots JM, Ros F, Miravitlles M; For the EVOCA study group. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract. 2008;62(4):585-592.
9. Wilkinson T, Wedzicha JA. Strategies for improving outcomes of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2006;1(3): 335-342.
10. Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341-349.
11. Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology - impact on approaches to risk stratification and therapy. Infect Dis Clin North Am. 2004;18(4):861-882.
12. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(2):150-157.
13. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348(26):2618-2625.
14. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117(5):1345-1352.
15. Woodhead M, Blasi F, Ewig S; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Resp J. 2005;26(6):1138-1180.
16. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. Available at: http://goldcopd.com. Accessed April 4, 2011.
17. Dever LL, Shashikumar K, Johanson WG. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig Drugs. 2002;11(7):911-925.
18. Sethi S. Antibiotics in acute exacerbations of chronic bronchitis. Expert Rev Anti Infect Ther. 2010;8(4):405-417.
19. Miravitlles M, Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest. 2004;125(3):811-813.
20. Wilson R, Allegra L, Huchon G; For the MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125(3):953-964.
21. Anthonisen NR, Maanfreda J, Warren C P, Hershfeld ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204.
22. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards - Eighth Edition. CLSI document M07-A8 Wayne, PA, 2009.
23. Miravitlles M. Moxifoxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis. 2007; 2(3):191-204.
24. Sethi S, Breton J, Wynne B. Effcacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 2005;49(1):153-160.
25. ® (amoxicillin/ clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004;53(SUPPL. 1):i3-i20.
26. Summary of Product Characteristics. Avelox 400 mg flm-coated tablets. Bayer Schering Pharma (Bayer UK). Available at: http://www.medicines.org.uk/EMC/medicine/11841/SPC/Avelox+400+mg+flm-coated+tablets. Accessed April 4, 2011.
27. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 (SUPPL. B):25-31; discussion 33-37.
28. Jones PW. Activity limitation and quality of life in COPD. COPD. 2007; 4(3):273-278.
29. Jones PW. The Acute Exacerbation of COPD Symptom Scale (AECB-SS). J COPD Management. 2006; Quarter 2, article 3.
30. Food and Drug Administration. Guidance for Industry Non-Inferiority Clinical Trials Additional. 2010. Available from: http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM202140.pdf. Accessed April 4, 2011.
31. Patel A, Wilson R. Newer fuoroquinolones in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3): 243-250.
32. Siddiqi A, Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Int J Chron Obstruc J Pulmon Dis. 2008;3(1):31-44.
33. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):369-374.
34. Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis. 1999;28(6):1344-1345.
35. Chodosh S. Clinical signifcance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest. 2005;127(6):2231-2236.
36. Wilson R, Jones P, Schaberg T; For the MOSAIC Study Group. Antibiotic treatment and factors infuencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax. 2006;61(4): 337-342.
37. Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67(5):491-492.
38. Hurst JR, Vestbo J, Anzueto A; for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.
39. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786-796.
40. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007; 29(3):527-534.
41. Dewan NA, Rafque S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest. 2000;117(3): 662-671.
42. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax. 2003;58(8):680-685.
43. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J. 2007;14(Suppl B):5B-32B.
44. Food and Drug Administration. Guidance for Industry. Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment. 2008. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070935. pdf. Accessed April 4, 2011.